MEDS trxade healt Inc. il futuro..

_Blizzard_

Nuovo Utente
Registrato
29/8/18
Messaggi
740
Punti reazioni
28
Finché non esce news o entra nelle grazie di qualche pumper la vedo difficile recuperare la posizione… allo stato attuale rimango in attesa e mi dedico ad altro…
 

beppofinanza

Nuovo Utente
Registrato
7/1/21
Messaggi
623
Punti reazioni
15
RIEF-TRxADE Health Announces Unit Signed Telemedicine Service Distribution Agreement

Feb 23 (Reuters) - TRxADE Health Inc :
* TRXADE HEALTH - CO ANNOUNCED THAT UNIT BONUM HEALTH SIGNED TELEMEDICINE SERVICE DISTRIBUTION AGREEMENT WITH COBORN’S INC
* TRXADE HEALTH - BONUM HEALTH TO PROVIDE AFFORDABLE TELE-MEDICINE, PRESCRIPTION DISCOUNT SAVINGS TO PATIENTS, CONSUMERS OF COBORN’S RETAIL STORES
 

_Blizzard_

Nuovo Utente
Registrato
29/8/18
Messaggi
740
Punti reazioni
28
Sempre in anche io, rimasto con tre posizioni aperte che però non intendo più mediare… non ho fretta, per cui attendo momenti migliori
Su ST danni earnings entro fine mese, vediamo un po’
 

kada1992

Nuovo Utente
Registrato
12/7/15
Messaggi
1.954
Punti reazioni
102
Sempre in anche io, rimasto con tre posizioni aperte che però non intendo più mediare… non ho fretta, per cui attendo momenti migliori
Su ST danni earnings entro fine mese, vediamo un po’

TRxADE HEALTH, INC. to Report Fourth Quarter and Year End 2021 Financial Results on Monday, March 28th at 5:00 p.m.


TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the fourth quarter and Year End 2021, after market close on March 28, 2022. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

In addition, management will host a conference call on Monday, March 28, 2022, at 5:00 p.m. Eastern time to discuss TRxADE HEALTH's fourth quarter and year end 2021 financial results. The call will conclude with a Q&A from participants.
 

kada1992

Nuovo Utente
Registrato
12/7/15
Messaggi
1.954
Punti reazioni
102
2 giorni di fila verde non capitavano da una vita
 

_Blizzard_

Nuovo Utente
Registrato
29/8/18
Messaggi
740
Punti reazioni
28
Non guardarla, lasciala fare... in questo momento è inutile: l'unica cosa positiva è che basta ancora una buona news e la riescono a pumpare... ora è di nuovo in mano agli shorter per cui... :rolleyes:
 

kada1992

Nuovo Utente
Registrato
12/7/15
Messaggi
1.954
Punti reazioni
102
TRxADE HEALTH Reports First Quarter Revenue Growth of 6% and Q1 2022 Financial Results


(NASDAQ:MEDS)("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced its financial results for the 2022 first quarter (Q1) ended March 31, 2022.

First Quarter 2022 and Subsequent Operational Highlights

TRxADE continued to expand the TRxADE drug procurement marketplace nationwide, adding 339 new registered members in Q1 2022, bringing the total registered members to approximately 13,475+ at March 31, 2022.

TRxADE announced a venture with Exchange Health, LLC, SOSRx, LLC. SOSRx will provide pharmaceutical manufacturers a single platform to optimize the sale and distribution of their inventory directly to large pharmaceutical buyers across multiple classes of trade. SOSRx opens the market to short dated, over stock and slow-moving pharmaceuticals that would otherwise be subject to destruction. TRxADE anticipates growth in 2022 as more progressive manufacturers are expected to address the public need for enhanced medication accessibility and reliable supply of cost-effective pharmaceuticals.

Management Commentary

"I am pleased with the growth we have experienced in our TRxADE and TRxADE Prime platforms for the first quarter of 2022. We have continued to drive our business forward, achieving several key milestones in our internal roadmap with a focus on innovation and development through our various complementary growth opportunities.

Our new venture, SOSRx, is an exciting addition that provides additional availability to short dated and overstocked drugs, with a goal to positively impact the public need for cost effective medication.

The TRxADE marketplace connects wholesalers and independent pharmacies and our SOSRx marketplace connects the manufacturers and wholesalers. Both the TRxADE and SOSRx marketplaces deliver radical price transparency, economies of scale and competition that benefit the independent pharmacies and wholesalers, while expanding the selling potential for such participants.

We believe the TRxADE and SOSRx platforms provide the opportunity to deliver more affordable prescription costs for consumers.

This is an exciting time for TRxADE, as we continue to position ourselves to create sustainable value for our shareholders," concluded Mr. Suren Ajjarapu, the Company's Chairman and Chief Executive Officer.

First Quarter 2022 Financial Summary

Revenues for the first quarter of 2022, increased 6% to $3.2 million, compared to revenue of $3.1 million in the same quarter last year. The increase in revenue was primarily due to revenue generated by the TRxADE Platform and TRxADE Prime.

Gross profit in the first quarter of 2022, decreased 4% to $1.3 million, or 41% of revenues, compared to gross profit of $1.4 million, or 45% of revenues, in the same quarter last year. The decrease in gross profit was primarily attributable to higher costs associated with TRxADE Prime transactions.

Operating expenses in the first quarter of 2022 were $2.3 million, compared to $2 million in the same quarter last year. This increase is primarily due to continued IT initiatives and increased salary and legal expenses.

Net loss in the first quarter of 2022 was ($1.0) million, or ($0.12) per basic and diluted share outstanding, compared to a net loss of ($0.7) million, or ($0.08) per basic and diluted share outstanding, in the same quarter last year.

Adjusted EBITDA, a non-GAAP financial measure, decreased to ($0.7) million for the first quarter of 2022, compared to ($0.5) million in the same quarter last year.See "Use of Non-GAAP Financial Information" below, and the reconciliation of Adjusted EBITDA to GAAP set forth at the end of this release.

Additional metrics related to our key performance are as follows:

As of March 31, 2022, the TRxADE Platform increased its registered users by 915 or 7.3% compared to March 31, 2021. For the quarter ended March 31, 2022, new registrations were 339 compared to 223 for the prior period in 2021. As of March 31, 2022, total registered users increased to 13,475 from 12,560 at March 31, 2021.

The table below summarizes the key metrics that management evaluated in relation to the activity on the TRxADE Platform for the three month period ended March 31, 2022 compared to the same period in 2021:

As of March 31, 2022, compared to the same period in 2021, Integra Pharma Solutions, LLC ("TRxADE Prime") increased processed sales volume over 600% and increased unique buyers on the TRxADE Prime platform by 184%.
 

kada1992

Nuovo Utente
Registrato
12/7/15
Messaggi
1.954
Punti reazioni
102
TRxADE HEALTH Reports First Quarter Revenue Growth of 6% and Q1 2022 Financial Results


(NASDAQ:MEDS)("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced its financial results for the 2022 first quarter (Q1) ended March 31, 2022.

First Quarter 2022 and Subsequent Operational Highlights

TRxADE continued to expand the TRxADE drug procurement marketplace nationwide, adding 339 new registered members in Q1 2022, bringing the total registered members to approximately 13,475+ at March 31, 2022.

TRxADE announced a venture with Exchange Health, LLC, SOSRx, LLC. SOSRx will provide pharmaceutical manufacturers a single platform to optimize the sale and distribution of their inventory directly to large pharmaceutical buyers across multiple classes of trade. SOSRx opens the market to short dated, over stock and slow-moving pharmaceuticals that would otherwise be subject to destruction. TRxADE anticipates growth in 2022 as more progressive manufacturers are expected to address the public need for enhanced medication accessibility and reliable supply of cost-effective pharmaceuticals.

Management Commentary

"I am pleased with the growth we have experienced in our TRxADE and TRxADE Prime platforms for the first quarter of 2022. We have continued to drive our business forward, achieving several key milestones in our internal roadmap with a focus on innovation and development through our various complementary growth opportunities.

Our new venture, SOSRx, is an exciting addition that provides additional availability to short dated and overstocked drugs, with a goal to positively impact the public need for cost effective medication.

The TRxADE marketplace connects wholesalers and independent pharmacies and our SOSRx marketplace connects the manufacturers and wholesalers. Both the TRxADE and SOSRx marketplaces deliver radical price transparency, economies of scale and competition that benefit the independent pharmacies and wholesalers, while expanding the selling potential for such participants.

We believe the TRxADE and SOSRx platforms provide the opportunity to deliver more affordable prescription costs for consumers.

This is an exciting time for TRxADE, as we continue to position ourselves to create sustainable value for our shareholders," concluded Mr. Suren Ajjarapu, the Company's Chairman and Chief Executive Officer.

First Quarter 2022 Financial Summary

Revenues for the first quarter of 2022, increased 6% to $3.2 million, compared to revenue of $3.1 million in the same quarter last year. The increase in revenue was primarily due to revenue generated by the TRxADE Platform and TRxADE Prime.

Gross profit in the first quarter of 2022, decreased 4% to $1.3 million, or 41% of revenues, compared to gross profit of $1.4 million, or 45% of revenues, in the same quarter last year. The decrease in gross profit was primarily attributable to higher costs associated with TRxADE Prime transactions.

Operating expenses in the first quarter of 2022 were $2.3 million, compared to $2 million in the same quarter last year. This increase is primarily due to continued IT initiatives and increased salary and legal expenses.

Net loss in the first quarter of 2022 was ($1.0) million, or ($0.12) per basic and diluted share outstanding, compared to a net loss of ($0.7) million, or ($0.08) per basic and diluted share outstanding, in the same quarter last year.

Adjusted EBITDA, a non-GAAP financial measure, decreased to ($0.7) million for the first quarter of 2022, compared to ($0.5) million in the same quarter last year.See "Use of Non-GAAP Financial Information" below, and the reconciliation of Adjusted EBITDA to GAAP set forth at the end of this release.

Additional metrics related to our key performance are as follows:

As of March 31, 2022, the TRxADE Platform increased its registered users by 915 or 7.3% compared to March 31, 2021. For the quarter ended March 31, 2022, new registrations were 339 compared to 223 for the prior period in 2021. As of March 31, 2022, total registered users increased to 13,475 from 12,560 at March 31, 2021.

The table below summarizes the key metrics that management evaluated in relation to the activity on the TRxADE Platform for the three month period ended March 31, 2022 compared to the same period in 2021:

As of March 31, 2022, compared to the same period in 2021, Integra Pharma Solutions, LLC ("TRxADE Prime") increased processed sales volume over 600% and increased unique buyers on the TRxADE Prime platform by 184%.
 

kada1992

Nuovo Utente
Registrato
12/7/15
Messaggi
1.954
Punti reazioni
102
TRxADE HEALTH Reports First Quarter Revenue Growth of 6% and Q1 2022 Financial Results

(NASDAQ:MEDS)("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced its financial results for the 2022 first quarter (Q1) ended March 31, 2022.

First Quarter 2022 and Subsequent Operational Highlights

TRxADE continued to expand the TRxADE drug procurement marketplace nationwide, adding 339 new registered members in Q1 2022, bringing the total registered members to approximately 13,475+ at March 31, 2022.

TRxADE announced a venture with Exchange Health, LLC, SOSRx, LLC. SOSRx will provide pharmaceutical manufacturers a single platform to optimize the sale and distribution of their inventory directly to large pharmaceutical buyers across multiple classes of trade. SOSRx opens the market to short dated, over stock and slow-moving pharmaceuticals that would otherwise be subject to destruction. TRxADE anticipates growth in 2022 as more progressive manufacturers are expected to address the public need for enhanced medication accessibility and reliable supply of cost-effective pharmaceuticals.

Management Commentary

"I am pleased with the growth we have experienced in our TRxADE and TRxADE Prime platforms for the first quarter of 2022. We have continued to drive our business forward, achieving several key milestones in our internal roadmap with a focus on innovation and development through our various complementary growth opportunities.

Our new venture, SOSRx, is an exciting addition that provides additional availability to short dated and overstocked drugs, with a goal to positively impact the public need for cost effective medication.

The TRxADE marketplace connects wholesalers and independent pharmacies and our SOSRx marketplace connects the manufacturers and wholesalers. Both the TRxADE and SOSRx marketplaces deliver radical price transparency, economies of scale and competition that benefit the independent pharmacies and wholesalers, while expanding the selling potential for such participants.

We believe the TRxADE and SOSRx platforms provide the opportunity to deliver more affordable prescription costs for consumers.

This is an exciting time for TRxADE, as we continue to position ourselves to create sustainable value for our shareholders," concluded Mr. Suren Ajjarapu, the Company's Chairman and Chief Executive Officer.

First Quarter 2022 Financial Summary

Revenues for the first quarter of 2022, increased 6% to $3.2 million, compared to revenue of $3.1 million in the same quarter last year. The increase in revenue was primarily due to revenue generated by the TRxADE Platform and TRxADE Prime.

Gross profit in the first quarter of 2022, decreased 4% to $1.3 million, or 41% of revenues, compared to gross profit of $1.4 million, or 45% of revenues, in the same quarter last year. The decrease in gross profit was primarily attributable to higher costs associated with TRxADE Prime transactions.

Operating expenses in the first quarter of 2022 were $2.3 million, compared to $2 million in the same quarter last year. This increase is primarily due to continued IT initiatives and increased salary and legal expenses.

Net loss in the first quarter of 2022 was ($1.0) million, or ($0.12) per basic and diluted share outstanding, compared to a net loss of ($0.7) million, or ($0.08) per basic and diluted share outstanding, in the same quarter last year.

Adjusted EBITDA, a non-GAAP financial measure, decreased to ($0.7) million for the first quarter of 2022, compared to ($0.5) million in the same quarter last year.See "Use of Non-GAAP Financial Information" below, and the reconciliation of Adjusted EBITDA to GAAP set forth at the end of this release.

Additional metrics related to our key performance are as follows:

As of March 31, 2022, the TRxADE Platform increased its registered users by 915 or 7.3% compared to March 31, 2021. For the quarter ended March 31, 2022, new registrations were 339 compared to 223 for the prior period in 2021. As of March 31, 2022, total registered users increased to 13,475 from 12,560 at March 31, 2021.

The table below summarizes the key metrics that management evaluated in relation to the activity on the TRxADE Platform for the three month period ended March 31, 2022 compared to the same period in 2021:

As of March 31, 2022, compared to the same period in 2021, Integra Pharma Solutions, LLC ("TRxADE Prime") increased processed sales volume over 600% and increased unique buyers on the TRxADE Prime platform by 184%.
 

kada1992

Nuovo Utente
Registrato
12/7/15
Messaggi
1.954
Punti reazioni
102
TRxADE HEALTH Reports First Quarter Revenue Growth of 6% and Q1 2022 Financial Results

First Quarter 2022 and Subsequent Operational Highlights

TRxADE continued to expand the TRxADE drug procurement marketplace nationwide, adding 339 new registered members in Q1 2022, bringing the total registered members to approximately 13,475+ at March 31, 2022.

TRxADE announced a venture with Exchange Health, LLC, SOSRx, LLC. SOSRx will provide pharmaceutical manufacturers a single platform to optimize the sale and distribution of their inventory directly to large pharmaceutical buyers across multiple classes of trade. SOSRx opens the market to short dated, over stock and slow-moving pharmaceuticals that would otherwise be subject to destruction. TRxADE anticipates growth in 2022 as more progressive manufacturers are expected to address the public need for enhanced medication accessibility and reliable supply of cost-effective pharmaceuticals.

Management Commentary

"I am pleased with the growth we have experienced in our TRxADE and TRxADE Prime platforms for the first quarter of 2022. We have continued to drive our business forward, achieving several key milestones in our internal roadmap with a focus on innovation and development through our various complementary growth opportunities.

Our new venture, SOSRx, is an exciting addition that provides additional availability to short dated and overstocked drugs, with a goal to positively impact the public need for cost effective medication.

The TRxADE marketplace connects wholesalers and independent pharmacies and our SOSRx marketplace connects the manufacturers and wholesalers. Both the TRxADE and SOSRx marketplaces deliver radical price transparency, economies of scale and competition that benefit the independent pharmacies and wholesalers, while expanding the selling potential for such participants.

We believe the TRxADE and SOSRx platforms provide the opportunity to deliver more affordable prescription costs for consumers.

This is an exciting time for TRxADE, as we continue to position ourselves to create sustainable value for our shareholders," concluded Mr. Suren Ajjarapu, the Company's Chairman and Chief Executive Officer.

First Quarter 2022 Financial Summary

Revenues for the first quarter of 2022, increased 6% to $3.2 million, compared to revenue of $3.1 million in the same quarter last year. The increase in revenue was primarily due to revenue generated by the TRxADE Platform and TRxADE Prime.

Gross profit in the first quarter of 2022, decreased 4% to $1.3 million, or 41% of revenues, compared to gross profit of $1.4 million, or 45% of revenues, in the same quarter last year. The decrease in gross profit was primarily attributable to higher costs associated with TRxADE Prime transactions.

Operating expenses in the first quarter of 2022 were $2.3 million, compared to $2 million in the same quarter last year. This increase is primarily due to continued IT initiatives and increased salary and legal expenses.

Net loss in the first quarter of 2022 was ($1.0) million, or ($0.12) per basic and diluted share outstanding, compared to a net loss of ($0.7) million, or ($0.08) per basic and diluted share outstanding, in the same quarter last year.

Adjusted EBITDA, a non-GAAP financial measure, decreased to ($0.7) million for the first quarter of 2022, compared to ($0.5) million in the same quarter last year.See "Use of Non-GAAP Financial Information" below, and the reconciliation of Adjusted EBITDA to GAAP set forth at the end of this release.

Additional metrics related to our key performance are as follows:

As of March 31, 2022, the TRxADE Platform increased its registered users by 915 or 7.3% compared to March 31, 2021. For the quarter ended March 31, 2022, new registrations were 339 compared to 223 for the prior period in 2021. As of March 31, 2022, total registered users increased to 13,475 from 12,560 at March 31, 2021.

The table below summarizes the key metrics that management evaluated in relation to the activity on the TRxADE Platform for the three month period ended March 31, 2022 compared to the same period in 2021:

As of March 31, 2022, compared to the same period in 2021, Integra Pharma Solutions, LLC ("TRxADE Prime") increased processed sales volume over 600% and increased unique buyers on the TRxADE Prime platform by 184%.